Literature DB >> 20811400

Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia.

A D Bulgar, M Snell, J R Donze, E B Kirkland, L Li, S Yang, Y Xu, S L Gerson, L Liu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20811400     DOI： 10.1038/leu.2010.166

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.

Authors:  Michael S Gordon; Lee S Rosen; David Mendelson; Ramesh K Ramanathan; Jonathan Goldman; Lili Liu; Yan Xu; Stanton L Gerson; Stephen P Anthony; William D Figg; Shawn Spencer; Bonne J Adams; Charles P Theuer; Bryan R Leigh; Glen J Weiss
Journal:  Invest New Drugs       Date:  2012-09-29       Impact factor: 3.850

2.  The C-terminal Domain (CTD) of Human DNA Glycosylase NEIL1 Is Required for Forming BERosome Repair Complex with DNA Replication Proteins at the Replicating Genome: DOMINANT NEGATIVE FUNCTION OF THE CTD.

Authors:  Pavana M Hegde; Arijit Dutta; Shiladitya Sengupta; Joy Mitra; Sanjay Adhikari; Alan E Tomkinson; Guo-Min Li; Istvan Boldogh; Tapas K Hazra; Sankar Mitra; Muralidhar L Hegde
Journal:  J Biol Chem       Date:  2015-07-01       Impact factor: 5.157

3.  Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors.

Authors:  Jennifer R Eads; Smitha S Krishnamurthi; Joel Saltzman; Joseph A Bokar; Panos Savvides; Neal J Meropol; Joseph Gibbons; Henry Koon; Neelesh Sharma; Lisa Rogers; John J Pink; Yan Xu; Jan H Beumer; John Riendeau; Pingfu Fu; Stanton L Gerson; Afshin Dowlati
Journal:  Invest New Drugs       Date:  2020-06-17       Impact factor: 3.850

4.  Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair.

Authors:  A D Bulgar; L D Weeks; Y Miao; S Yang; Y Xu; C Guo; S Markowitz; N Oleinick; S L Gerson; L Liu
Journal:  Cell Death Dis       Date:  2012-01-12       Impact factor: 8.469

5.  Single cell profiling of phospho-protein levels in chronic lymphocytic leukemia.

Authors:  Ida K Myhrvold; Andrea Cremaschi; Johanne U Hermansen; Geir E Tjønnfjord; Ludvig A Munthe; Kjetil Taskén; Sigrid S Skånland
Journal:  Oncotarget       Date:  2018-01-04

Review 6.  Inhibitors of DNA Glycosylases as Prospective Drugs.

Authors:  Grigory V Mechetin; Anton V Endutkin; Evgeniia A Diatlova; Dmitry O Zharkov
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

Review 7.  DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias.

Authors:  Ida Casorelli; Cecilia Bossa; Margherita Bignami
Journal:  Int J Environ Res Public Health       Date:  2012-07-27       Impact factor: 3.390

Review 8.  New insights into the synergism of nucleoside analogs with radiotherapy.

Authors:  Michael W Lee; William B Parker; Bo Xu
Journal:  Radiat Oncol       Date:  2013-09-26       Impact factor: 3.481

9.  Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs.

Authors:  Eliza Starczewska; Maxime Beyaert; Lucienne Michaux; Marie-Christiane Vekemans; Pascale Saussoy; Vanesa Bol; Ainhoa Arana Echarri; Caroline Smal; Eric Van Den Neste; Françoise Bontemps
Journal:  Oncotarget       Date:  2016-06-21

10.  Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies.

Authors:  Paolo F Caimi; Brenda W Cooper; Basem M William; Afshin Dowlati; Paul M Barr; Pingfu Fu; John Pink; Yan Xu; Hillard M Lazarus; Marcos de Lima; Stanton L Gerson
Journal:  Oncotarget       Date:  2017-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.